GLP-1 agonist

Beware of knock-off Ozempic

The shortage of Ozempic has led to many compounding pharmacies using a knock-off version of semaglutide that has not been FDA approved.

Newer GLP-1 agonists like Ozempic and Wegovy may increase thyroid cancer risks significantly more than what the current evidence shows.

Semaglutide currently comes in 3 different forms: Wegovy, Ozempic, and Rybelsus, each with their own pros and cons and potential side effects.

Preliminary studies show Mounjaro (tirzepatide) to be more effective and have less side effects than Wegovy (semaglutide).

Wegovy is currently one of the strongest GLP-1 agonists for weight loss. However, it also has the strongest side effects and highest costs.

Wegovy is another GLP-1 agonist that’s essentially the same as Ozempic, just given at a higher dose and marketed for weight loss.

Saxenda is the only drug approved for weight loss, although Ozempic has very similar effects and is only injected once a week.

Saxenda is a GLP-1 agonist with effects on blood sugar for diabetes, as well as appetite suppression for weight loss.